Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG

The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert & Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 2023 financial year.

 

As in the previous year, the Annual General Meeting was held as an in-person event at Eckert & Ziegler SE's headquarters in Berlin. A total of 57.6% of the company's share capital was represented.

The detailed voting results of the Annual General Meeting and the presentation by the Chairman of the Executive Board are published here on the Eckert & Ziegler SE website.

About Eckert & Ziegler
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives.

Your contact:
Eckert & Ziegler SE
Karolin Riehle
Investor Relations
Robert-Rössle-Str. 10
13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138
karolin.riehle@noSpamezag.de
www.ezag.com 

 

Back